This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
What are the three main challenges of monitoring pharmaceuticals in the environment? Andreas Häner (AH): Roche, along with other pharmaceutical companies, acknowledges concerns about pharmaceuticals in the environment (PiE).
A new water-based reactor system, developed by scientists at Rice University, promises to bring significant advances to pharmaceuticalmanufacturing. The innovation beckons a major shift in industrial chemistry, helping companies to reduce solvent waste, improve workplace safety, and lower production costs.
Doctors, caregivers, life sciences companies, and even companies in other industries have attempted to answer this question for as long as medications have been available. Needles cause patients pain, anxiety, pose safety risks, and for some people receiving injection therapy is a traumatic experience. But it is not a simple answer.
It is noteworthy that Malaysia has a pharmaceuticalmanufacturing sector that almost exclusively produces generic drugs, with sales revenues amounting to only 1.5% of gross domestic product (GDP). I also note that the five largest companies typically sell originator drugs and account for 47 percent of total drug imports.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content